SurModics/$SRDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About SurModics
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
Ticker
$SRDX
Sector
Primary listing
Employees
389
Headquarters
Website
SurModics Metrics
BasicAdvanced
$383M
-
-$1.24
1.31
-
Price and volume
Market cap
$383M
Beta
1.31
52-week high
$40.21
52-week low
$25.87
Average daily volume
102K
Financial strength
Current ratio
3.909
Quick ratio
2.883
Long term debt to equity
28.352
Total debt to equity
26.652
Interest coverage (TTM)
-0.40%
Profitability
EBITDA (TTM)
7.054
Gross margin (TTM)
76.22%
Net profit margin (TTM)
-14.59%
Operating margin (TTM)
-1.20%
Effective tax rate (TTM)
-19.98%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-0.52%
Return on equity (TTM)
-15.36%
Valuation
Price to revenue (TTM)
3.159
Price to book
3.44
Price to tangible book (TTM)
8.83
Price to free cash flow (TTM)
-107.617
Free cash flow yield (TTM)
-0.93%
Free cash flow per share (TTM)
-0.249
Growth
Revenue change (TTM)
-0.02%
Earnings per share change (TTM)
1,151.84%
3-year revenue growth (CAGR)
7.25%
10-year revenue growth (CAGR)
7.27%
3-year earnings per share growth (CAGR)
10.31%
10-year earnings per share growth (CAGR)
2.59%
What the Analysts think about SurModics
Analyst ratings (Buy, Hold, Sell) for SurModics stock.
Bulls say / Bears say
Excluding SurVeil DCB license fee revenue, total Q3 FY2025 sales rose 1% year-over-year to $29.6 million, led by strong performance in coating royalties and license fees. (Business Wire)
The Pounce Thrombectomy Platform delivered 35% year-over-year sales growth in Q3 FY2025, reflecting strong adoption of its vascular intervention devices. (Business Wire)
In Vitro Diagnostics revenue increased 6% to $7.4 million in Q3 FY2025, driven by broad‐based growth across reagents and microarray surface products. (Business Wire)
Total revenue for Q3 FY2025 declined 3% year-over-year to $29.6 million, reflecting weakness in its core Medical Device segment which saw sales fall 4.9% to $22.2 million. (Business Wire)
Product gross margin contracted to 48.8% from 51.9% in Q3 FY2025, driven by under-absorption and inventory write-downs related to below-scale production of the SurVeil drug-coated balloon. (Nasdaq)
The FTC filed an administrative complaint on March 6, 2025 to block the GTCR acquisition of SurModics over antitrust concerns, creating material regulatory uncertainty and potential legal costs. (FTC)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
SurModics Financial Performance
Revenues and expenses
SurModics Earnings Performance
Company profitability
SurModics News
AllArticlesVideos
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
Business Wire6 days ago
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
Business Wire7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SurModics stock?
SurModics (SRDX) has a market cap of $383M as of November 10, 2025.
What is the P/E ratio for SurModics stock?
The price to earnings (P/E) ratio for SurModics (SRDX) stock is 0 as of November 10, 2025.
Does SurModics stock pay dividends?
No, SurModics (SRDX) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next SurModics dividend payment date?
SurModics (SRDX) stock does not pay dividends to its shareholders.
What is the beta indicator for SurModics?
SurModics (SRDX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.